Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacogenomics (London)

• Publication date

  2005-11-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14622416.6.2.115PMID 15882131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE

  2005cited by this paper
• FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

  2005cited by this paper
• MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

  2004cited by this paper
• MDR-1 C3435T Polymorphism Influences Cyclosporine A Dose Requirement in Liver-Transplant Recipients

  2004cited by this paper
• The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

  2004cited by this paper
• CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.

  2004cited by this paper
• ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins

  2004cited by this paper
• Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs

  2004cited by this paper
• Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

  2004influential reference
• A variant 2677A allele of the MDR1 gene affects fexofenadine disposition

  2004cited by this paper
• Expression of Pregnane-X-Receptor Transcript in Peripheral Blood Mononuclear Cells and Correlation with Mdr1 Mrna

  2004cited by this paper
• The Q141K single-nucleotide polymorphism impacts the transporter activity of ABCG2.

  2004cited by this paper
• Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study

  2004cited by this paper
• Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme*

  2004cited by this paper
• Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism

  2004cited by this paper
• Functional Analysis of SNPs Variants of BCRP/ABCG2

  2004cited by this paper
• Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1).

  2004cited by this paper
• Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene

  2004cited by this paper
• Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.

  2004cited by this paper
• CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation

  2004cited by this paper
• MDR1 gene polymorphism in ulcerative colitis.

  2004cited by this paper
• Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.

  2004cited by this paper
• ABCG2 Pharmacogenetics

  2004influential reference
• HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)

  2004cited by this paper
• Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition

  2004cited by this paper
• Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

  2004cited by this paper
• Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis

  2004cited by this paper
• Dexamethasone as a probe for docetaxel clearance

  2004cited by this paper
• Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2*

  2004cited by this paper
• Mutations

  2004cited by this paper
• Analysis of MDR1 haplotypes in Parkinson's disease in a white population.

  2004cited by this paper
• Haplotype-Oriented Genetic Analysis and Functional Assessment of Promoter Variants in the MDR1 (ABCB1) Gene

  2004cited by this paper
• Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

  2004cited by this paper
• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  2004cited by this paper
• Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan.

  2004cited by this paper
• The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population.

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors

  2004cited by this paper
• Pharmacogenomics of MDR1/ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies

  2004cited by this paper
• Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR‐1, CYP3A4, and CYP3A5 genes

  2004cited by this paper
• Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

  2004cited by this paper
• MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment.

  2004cited by this paper
• Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023

  2004cited by this paper
• Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia

  2004cited by this paper
• The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes.

  2004cited by this paper
• Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population.

  2003cited by this paper
• No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects

  2003cited by this paper
• Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients.

  2003cited by this paper
• Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene

  2003cited by this paper
• Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers.

  2003cited by this paper
• Digoxin pharmacokinetics and MDR1 genetic polymorphisms

  2003cited by this paper
• Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

  2003cited by this paper
• An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth

  2003cited by this paper
• Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

  2003cited by this paper
• Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.

  2003cited by this paper
• The role of ABC transporters in clinical practice.

  2003cited by this paper
• Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon.

  2003cited by this paper
• Breast cancer resistance protein exports sulfated estrogens but not free estrogens.

  2003cited by this paper
• Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.

  2003cited by this paper
• Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.

  2003cited by this paper
• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  2003cited by this paper
• RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

  2003cited by this paper
• Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2).

  2003cited by this paper
• Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.

  2003cited by this paper
• Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.

  2003cited by this paper
• A multidrug efflux phenotype mutant of Streptococcus pyogenes.

  2003cited by this paper
• Sterol Transport by the Human Breast Cancer Resistance Protein (ABCG2) Expressed in Lactococcus lactis*

  2003cited by this paper
• Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

  2003cited by this paper
• MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study

  2003cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper
• Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.

  2003cited by this paper
• MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

  2003cited by this paper
• ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation.

  2003cited by this paper
• Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

  2003cited by this paper
• Natural variation in human membrane transporter genes reveals evolutionary and functional constraints

  2003cited by this paper
• Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.

  2003cited by this paper
• Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

  2003cited by this paper
• Irinotecan pathway genotype analysis to predict pharmacokinetics.

  2003cited by this paper
• MDR1 Ala893 polymorphism is associated with inflammatory bowel disease.

  2003cited by this paper
• Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.

  2003cited by this paper
• A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.

  2003cited by this paper
• Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

  2003cited by this paper
• The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

  2003cited by this paper
• Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

  2003influential reference
• [MDR1 genotypes related to pharmacokinetics and MDR1 expression].

  2003cited by this paper
• MDR1 Genotype-Related Duodenal Absorption Rate of Digoxin in Healthy Japanese Subjects

  2003cited by this paper
• MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

  2003cited by this paper
• MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant Patients

  2003cited by this paper
• Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.

  2003cited by this paper
• Influence of the functional polymorphisms of the MDR-1 gene on vincristine pharmacokineties in childhood acute lymphoblastic leukemia.

  2003cited by this paper
• Role of P-Glycoprotein in Pharmacokinetics

  2003cited by this paper
• Pharmacogenomics--drug disposition, drug targets, and side effects.

  2003cited by this paper
• Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

  2003influential reference
• Effects of Grapefruit Juice on Intestinal P‐glycoprotein: Evaluation Using Digoxin in Humans

  2003cited by this paper

• The effect of microenvironmental viscosity on the emergence of colon cancer cell resistance to doxorubicin.

  2025cites this paper
• Mechanistic Insights into the Anticancer Action of Novel 2‑Hydroxy-1,4-naphthoquinone Thiol Derivatives

  2025cites this paper
• Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives

  2024cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Drug resistance of hepatoma cells induced by ATP‑binding cassette transporter G2 by reducing intracellular drug concentration.

  2023cites this paper
• Sex differences in hepatocellular carcinoma indicated BEX4 as a potential target to improve efficacy of lenvatinib plus immune checkpoint inhibitors

  2022cites this paper
• [Effects of Extracellular Vesicles on the Drug Resistance of Lung Adenocarcinoma Cells by Modulating the ATP Binding Cassette Transporter G2].

  2022cites this paper
• Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin

  2021cites this paper
• Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer

  2021cites this paper
• Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.

  2021cites this paper
• Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

  2021cites this paper
• The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors

  2021cites this paper
• Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity

  2020cites this paper
• A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes

  2020cites this paper
• Influence of ABCB‐1, ERCC‐1 and ERCC‐2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India

  2020cites this paper
• Association between polymorphisms in microRNA seed region and warfarin stable dose

  2020cites this paper
• Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients.

  2019cites this paper
• Ovarian damage from chemotherapy and current approaches to its protection

  2019cites this paper
• Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.

  2019cites this paper
• Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.

  2019cites this paper
• Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population

  2018cites this paper
• Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis

  2018cites this paper
• Association between multidrug resistance-1 C3435T gene polymorphism and right ventricular dysfunction in patients with chronic obstructive pulmonary disease: cross-sectional study

  2018cites this paper
• Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients

  2018cites this paper
• Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.

  2017cites this paper
• Prevention of chemotherapy-induced ovarian damage.

  2016cites this paper
• Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.

  2016cites this paper
• P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy

  2016cites this paper
• Applied Nanotechnology and Nanoscience in Orthopedic Oncology.

  2016cites this paper
• Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia

  2016cites this paper
• Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

  2015cites this paper
• Investigation of the association between genetics, drug exposure and statin-induced muscle toxicity

  2015cites this paper
• Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients

  2015cites this paper
• Anticancer Activity of Polyether Ionophore-Salinomycin.

  2015cites this paper
• Structure and Biological Activity of Polyether Ionophores and Their Semisynthetic Derivatives

  2015cites this paper
• A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

  2015cites this paper
• Concepts of Anticancer Treatment and Pharmacogenomics in Cancer Treatments

  2015cites this paper
• Preclinical Approaches to the Protection of Ovarian Function

  2015cites this paper
• SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2

  2015cites this paper
• Functional Polymorphisms of the ABCG2 Gene Are Associated with Gout Disease in the Chinese Han Male Population

  2014cites this paper
• Investigations into rat hepatobiliary drug clearance pathways in early drug discovery.

  2014cites this paper
• ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines

  2014cites this paper
• High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?

  2014cites this paper
• Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

  2014cites this paper
• What do drug transporters really do?

  2014cites this paper
• Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

  2014cites this paper
• Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis

  2014cites this paper
• Farmakogenetika: individualizirani način liječenja genetičkih poremećaja

  2014cites this paper
• Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know.

  2014cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2014cites this paper
• Traitement par erlotinib après une toxicité hépatique induite par le géfitinib : revue de la littérature à propos d’une observation

  2014cites this paper
• Chapter 17 – Pharmacokinetic Pharmacogenomics

  2014cites this paper
• [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].

  2014cites this paper
• 14. BCRP (ABCG2)

  2013cites this paper
• Polyether ionophores-promising bioactive molecules for cancer therapy.

  2012cites this paper
• Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression

  2012cites this paper
• The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.

  2012cites this paper
• GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS(ABCG2, ABCB1) AND GEFITINIB TOXICITY

  2012cites this paper
• Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells.

  2011cites this paper
• Investigating a co-operative link between TGF-β and Lyn kinase in Chronic Myeloid Leukaemia

  2011cites this paper
• The challenge of exploiting ABCG2 in the clinic.

  2011cites this paper
• A new frontier in personalized cancer therapy: mapping molecular changes.

  2011cites this paper
• Targeting the Chronic Myeloid Leukemia Stem Cell: A Paradigm for the Curative Treatment of Human Malignancies

  2011cites this paper
• Nanoparticles: A Promising Modality in the Treatment of Sarcomas

  2011cites this paper
• Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome

  2011cites this paper
• Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

  2011cites this paper
• ATP-binding cassette efflux transporters in human placenta.

  2011cites this paper
• Influencia de la proteína de resistencia del cáncer de mama (bcrp) en la farmacocinética de los antirretrovirales

  2011cites this paper
• The Promise of Individualized Therapy

  2010cites this paper
• Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

  2010cites this paper
• On mechanisms of drug resistance in acute myeloid leukemia

  2010cites this paper
• Impact of breast cancer resistance protein on cancer treatment outcomes.

  2010cites this paper
• Chapter 6 - Biomarkers in Multiple Sclerosis

  2010cites this paper
• Multi-Drug Resistance in Cancer

  2010cites this paper
• Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

  2010cites this paper
• Pharmacogenetics of Membrane Transporters: An Update on Current Approaches

  2010influential citation
• Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

  2010cites this paper
• different clinical responses to imatinib mesylate CML stem/progenitor cells that correlate with + Properties of CD34

  2010cites this paper
• Insights into the stem cells of chronic myeloid leukemia

  2010cites this paper
• Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

  2009cites this paper
• Pharmacology, Pharmacogenetics, and Pharmacoepidemiology: Three Ps of Individualized Therapy

  2009cites this paper
• Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

  2009cites this paper
• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  2009cites this paper
• ABCG2: a perspective.

  2009cites this paper
• Identification of Compounds that Correlate with ABCG2 Transporter Function in the National Cancer Institute Anticancer Drug Screen

  2009cites this paper
• Chemotherapy in the Pediatric Patient

  2009cites this paper
• Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

  2009cites this paper
• Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs

  2008cites this paper
• The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

  2008cites this paper
• Genetic Variation in Drug Transporters in Ethnic Populations

  2008cites this paper
• Pharmacogenomic importance of ABCG2.

  2008cites this paper
• ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition.

  2008cites this paper
• Stem Cell Biomarkers in Chronic Myeloid Leukemia

  2008cites this paper
• Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib

  2008cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2008cites this paper
• The Role of Efflux and Uptake Transporters in Lapatinib ( Tykerb , GW 572016 ) Disposition and Drug Interactions

  2008cites this paper
• Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

  2008cites this paper
• Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival

  2008cites this paper
• Role of transporters in pancreatic cancer drug resistance

  2007cites this paper
• Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics

  2007cites this paper